{"id":11115,"date":"2023-11-08T09:45:17","date_gmt":"2023-11-08T08:45:17","guid":{"rendered":"https:\/\/irlab.se\/?page_id=11115"},"modified":"2026-10-20T15:55:14","modified_gmt":"2026-10-20T13:55:14","slug":"valberedning-infor-arsstamma-2024","status":"publish","type":"page","link":"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/","title":{"rendered":"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027"},"content":{"rendered":"\n<h1 id=\"foregaende-valberedning\" class=\"wp-block-heading\">Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Enligt den instruktion f\u00f6r valberedning i IRLAB Therapeutics AB som antogs p\u00e5 \u00e5rsst\u00e4mman den 22 maj 2024 ska valberedningen, ut\u00f6ver styrelsens ordf\u00f6rande, best\u00e5 av representanter f\u00f6r de tre st\u00f6rsta aktie\u00e4garna, eller \u00e4gargrupperna, av Euroclear Sweden AB registrerade per den sista bankdagen i augusti 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2027 har f\u00f6ljande sammans\u00e4ttning:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Daniel Johnsson<\/strong>, entrepren\u00f6r, bolagsutvecklare och investerare, utsedd av en \u00e4gargrupp som representerar cirka 11 procent av aktier och r\u00f6ster (ordf\u00f6rande);<\/li>\n\n\n\n<li><strong>Joakim Tedroff<\/strong>, Chief Medical Officer (CMO) p\u00e5 IRLAB och en av IRLAB:s grundare. Utsedd av en \u00e4gargrupp best\u00e5ende av bolagets grundare m.fl. som representerar cirka 8 procent av aktier och r\u00f6ster; samt<\/li>\n\n\n\n<li><strong>Patrik Mossberg<\/strong>, vd och ordf\u00f6rande i Marinvest\u00a0 ca 3 procent av aktier och r\u00f6ster; samt<\/li>\n\n\n\n<li><strong>Janne Backman<\/strong>, styrelseordf\u00f6rande i IRLAB Therapeutics AB.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Daniel Johnsson har utsetts till valberedningens ordf\u00f6rande.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Valberedningens ledam\u00f6ter \u00e4r utsedda av \u00e4gare i IRLAB Therapeutics AB som sammanlagt representerar cirka 22 procent av antalet r\u00f6stber\u00e4ttigade aktier i bolaget enligt \u00e4garf\u00f6rh\u00e5llanden per den sista bankdagen i augusti 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Information om valberedningens arbete samt instruktionen till valberedningen \u00e5terfinns p\u00e5 bolagets hemsida under sektionen f\u00f6r\u00a0<a href=\"https:\/\/irlab.se\/sv\/bolagsstyrning\/\" target=\"_blank\" rel=\"noreferrer noopener\">bolagsstyrning<\/a>. Valberedningens f\u00f6rslag kommer att presenteras i kallelsen till \u00e5rsst\u00e4mman 2027 samt p\u00e5 bolagets webbplats,\u00a0<a href=\"https:\/\/irlab.se\/sv\/bolagsstyrning\/bolagsstamma\/\" target=\"_blank\" rel=\"noreferrer noopener\">www.irlab.se<\/a>. \u00c5rsst\u00e4mman 2027 \u00e4r planerad att \u00e4ga rum den 3 Juni 2027.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aktie\u00e4gare som \u00f6nskade l\u00e4mna f\u00f6rslag till valberedningen skulle g\u00f6ra detta skriftligen, senast den 31\u00a0januari 2027, per e-post\u00a0<a href=\"mailto:ir@irlab.se\" target=\"_blank\" rel=\"noreferrer noopener\">ir@irlab.se<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 Enligt den instruktion f\u00f6r valberedning i IRLAB Therapeutics AB som antogs p\u00e5 \u00e5rsst\u00e4mman den 22 maj 2024 ska valberedningen, ut\u00f6ver styrelsens ordf\u00f6rande, best\u00e5 av representanter f\u00f6r de tre st\u00f6rsta aktie\u00e4garna, eller \u00e4gargrupperna, av Euroclear Sweden AB registrerade per den sista bankdagen i augusti 2026. Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2027 har f\u00f6ljande sammans\u00e4ttning: [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":578,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11115","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 Enligt den instruktion f\u00f6r valberedning i IRLAB Therapeutics AB som antogs p\u00e5 \u00e5rsst\u00e4mman den 22 maj 2024 ska valberedningen, ut\u00f6ver styrelsens ordf\u00f6rande, best\u00e5 av representanter f\u00f6r de tre st\u00f6rsta aktie\u00e4garna, eller \u00e4gargrupperna, av Euroclear Sweden AB registrerade per den sista bankdagen i augusti 2026. Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2027 har f\u00f6ljande sammans\u00e4ttning: [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-20T13:55:14+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/irlab.se\\\/sv\\\/bolagsstyrning\\\/nomination-committee\\\/valberedning-infor-arsstamma-2024\\\/\",\"url\":\"https:\\\/\\\/irlab.se\\\/sv\\\/bolagsstyrning\\\/nomination-committee\\\/valberedning-infor-arsstamma-2024\\\/\",\"name\":\"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/irlab.se\\\/#website\"},\"datePublished\":\"2023-11-08T08:45:17+00:00\",\"dateModified\":\"2026-10-20T13:55:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/irlab.se\\\/sv\\\/bolagsstyrning\\\/nomination-committee\\\/valberedning-infor-arsstamma-2024\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/irlab.se\\\/sv\\\/bolagsstyrning\\\/nomination-committee\\\/valberedning-infor-arsstamma-2024\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/irlab.se\\\/sv\\\/bolagsstyrning\\\/nomination-committee\\\/valberedning-infor-arsstamma-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/irlab.se\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bolagsstyrning\",\"item\":\"https:\\\/\\\/irlab.se\\\/sv\\\/bolagsstyrning\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Valberedning\",\"item\":\"https:\\\/\\\/irlab.se\\\/sv\\\/bolagsstyrning\\\/nomination-committee\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/irlab.se\\\/#website\",\"url\":\"https:\\\/\\\/irlab.se\\\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/irlab.se\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/","og_locale":"sv_SE","og_type":"article","og_title":"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 - IRLAB","og_description":"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 Enligt den instruktion f\u00f6r valberedning i IRLAB Therapeutics AB som antogs p\u00e5 \u00e5rsst\u00e4mman den 22 maj 2024 ska valberedningen, ut\u00f6ver styrelsens ordf\u00f6rande, best\u00e5 av representanter f\u00f6r de tre st\u00f6rsta aktie\u00e4garna, eller \u00e4gargrupperna, av Euroclear Sweden AB registrerade per den sista bankdagen i augusti 2026. Valberedningen inf\u00f6r \u00e5rsst\u00e4mman 2027 har f\u00f6ljande sammans\u00e4ttning: [&hellip;]","og_url":"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/","og_site_name":"IRLAB","article_modified_time":"2026-10-20T13:55:14+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/","url":"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/","name":"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2023-11-08T08:45:17+00:00","dateModified":"2026-10-20T13:55:14+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/valberedning-infor-arsstamma-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"Bolagsstyrning","item":"https:\/\/irlab.se\/sv\/bolagsstyrning\/"},{"@type":"ListItem","position":3,"name":"Valberedning","item":"https:\/\/irlab.se\/sv\/bolagsstyrning\/nomination-committee\/"},{"@type":"ListItem","position":4,"name":"Valberedning inf\u00f6r \u00e5rsst\u00e4mma 2027"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/11115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=11115"}],"version-history":[{"count":10,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/11115\/revisions"}],"predecessor-version":[{"id":13661,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/11115\/revisions\/13661"}],"up":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/pages\/578"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=11115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}